Eganelisib
Eganelisib (IPI549) is a potent and selective PI3Kγ inhibitor with an IC50 of 16 nM. Eganelisib shows >100-fold selectivity over other lipid and protein kinases[1].
Product Specifications
CAS Number
1693758-51-8
Product Name Alternative
IPI-549
UNSPSC
12352005
Hazard Statement
H302, H315, H319, H335
Target
PI3K
Type
Reference compound
Related Pathways
PI3K/Akt/mTOR
Applications
Cancer-Kinase/protease
Field of Research
Cancer
Assay Protocol
https://www.medchemexpress.com/IPI549.html
Concentration
10mM
Purity
99.68
Solubility
DMSO : 25 mg/mL (ultrasonic)
Smiles
O=C(C1=C2N=CC=CN2N=C1N)N[C@H](C3=CC4=C(C(N3C5=CC=CC=C5)=O)C(C#CC6=CN(C)N=C6)=CC=C4)C
Molecular Formula
C30H24N8O2
Molecular Weight
528.56
Precautions
H302, H315, H319, H335
References & Citations
[1]Evans CA, et al. Discovery of a Selective Phosphoinositide-3-Kinase (PI3K) -γ Inhibitor (IPI-549) as an Immuno-Oncology Clinical Candidate. ACS Med Chem Lett. 2016 Jul 22;7 (9) :862-7.|[2]De Henau O, et al. Overcoming resistance to checkpoint blockade therapy by targeting PI3Kγ in myeloid cells. Nature. 2016 Nov 17;539 (7629) :443-447.
Shipping Conditions
Room Temperature
Storage Conditions
-20°C, 3 years; 4°C, 2 years (Powder)
Scientific Category
Reference compound1
Clinical Information
Phase 2
Isoform
PI3Kα; PI3Kβ; PI3Kγ
Available Sizes
Frequently Asked Questions
More Discoveries
Explore Other Products
Browse additional items from our catalog
K3400003 1.0 µg DNA
Ssty1 sgRNA CRISPR Lentivector (Mouse) (Target 2)
Sign In for Pricing
View Details 